Showing results (31-40 of 148) with videos related to

Sort By:
Pageof 15
Haematologica|December 30, 2006
Parathyroid-hormone-related-protein-associated hypercalcemia in a patient with CLL-type low-grade leukemic B-cell lymphomaBjörn Schöttker, Werner Heinz, Florian Weissinger, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|November 25, 2025
Effects of Empagliflozin in Heart Failure Patients with Type 2 Diabetes: A Biomarker PerspectiveAsmaa Elrakaybi, Qian Zhou, Günter Päth, et al.
Diabetes Technology & Therapeutics|June 1, 2019
Comparative Dose Accuracy of Durable and Patch Insulin Pumps Under Laboratory ConditionsKatharina Laubner, Eva Singler, Jan Straetener, et al.
Diabetes, Obesity & Metabolism|September 13, 2021
Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safetyJochen Seufert, Peter Wiesli, Andreas Fritsche, et al.
Diabetes|November 25, 2005
Inhibition of preproinsulin gene expression by leptin induction of suppressor of cytokine signaling 3 in pancreatic beta-cellsKatharina Laubner, Timothy J Kieffer, Ni T Lam, et al.
Innere Medizin (Heidelberg, Germany)|March 5, 2026
[Preventive fields in endocrinology/diabetology-The big five]Martin Pfohl, Martin Reincke, Jochen Seufert, et al.
Tissue Engineering|March 11, 2004
Three-dimensional in vitro model of adipogenesis: comparison of culture conditionsClaudia Fischbach, Jochen Seufert, Harald Staiger, et al.
Diabetes, Obesity & Metabolism|September 27, 2017
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trialsSerge Jabbour, Jochen Seufert, Andre Scheen, et al.
BMC Endocrine Disorders|October 9, 2015
Treatment intensification using long-acting insulin -predictors of future basal insulin supported oral therapy in the DIVE registryThomas Danne, Tobias Bluhmki, Jochen Seufert, et al.
Cytotherapy|April 22, 2011
PDX1- and NGN3-mediated in vitro reprogramming of human bone marrow-derived mesenchymal stromal cells into pancreatic endocrine lineagesCatarina Limbert, Günter Päth, Regina Ebert, et al.
Pageof 15